Evidence map›Paper›PMID 29568203›Full record

ArticleWorld journal of gastroenterology2018

Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions.

Abdel-Rahman N Zekri, Somaya El Deeb, Abeer A Bahnassy, Abeer M Badr, Mona S Abdellateif, Gamal Esmat, Hosny Salama, Marwa Mohanad, Ahmed Esam El-Dien, Shimaa Rabah and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Abdel-Rahman N ZekriMolecular Virology and Immunology Unit, Department of Cancer Biology, National Cancer Institute, Cairo University, Cairo 11976, Egypt. ncizekri@yahoo.com.
Somaya El DeebDepartment of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt.
Abeer A BahnassyDepartment of Pathology, National Cancer Institute, Cairo University, Cairo 11976, Egypt.
Abeer M BadrDepartment of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt.
Mona S AbdellateifMedical Biochemistry and Molecular Biology, Department of Cancer Biology, National Cancer Institute, Cairo University, Cairo 11976, Egypt.
Gamal EsmatDepartment of Hepatology and Tropical Medicine, Faculty of Medicine, Cairo University, Cairo 11441, Egypt.
Hosny SalamaDepartment of Hepatology and Tropical Medicine, Faculty of Medicine, Cairo University, Cairo 11441, Egypt.
Marwa MohanadDepartment of Biochemistry, Misr University for Science and Technology, 6th October 12945, Giza Governorate, Egypt.
Ahmed Esam El-DienDepartment of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt.
Shimaa RabahDepartment of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt.
Assmaa Abd ElkaderDepartment of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt.
Institute of Zoology · KZCairo University · EGMisr University for Science and Technology · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess the levels of different immune modulators in patients with hepatocellular carcinoma (HCC), in relation to other hepatic diseases.

methodsEighty-eight patients were included in the current study and represented patients with HCC (20), liver cirrhosis (28) and chronic hepatitis (CH; 25), and normal controls (NC; 15). Peripheral blood was isolated for immunophenotyping of active myeloid dendritic cells (mDCs; CD1c and CD40), mature inactive myeloid cells (CD1c and HLA), active plasmacytoid cells (pDCs; CD303 and CD40), mature inactive pDCs (CD30 and HLA), active natural killer (NK) cells (CD56 and CD161), active NK cells (CD56 and CD314) and inactive NK cells (CD56 and CD158) was done by flow cytometry. Serum levels of interleukin (IL)-2, IL-10, IL-12, IL-1β, interferon (IFN)-α, IFN-γ and tumor necrosis factor (TNF)-αR2 were assessed by ELISA.

resultsActive mDCs (CD1C+/CD40+) and inactive mDCs (CD1c+/HLA+) were significantly decreased in HCC patients in relation to NC (

conclusionNKG2D, CD40, IL-2 and IL-10 are important modulators in the development and progression of HCC.

Indexed as

AdultCarcinogenesisCarcinoma, HepatocellularCytokinesDisease ProgressionFemaleHepatitis, ChronicHumansImmunity, CellularImmunity, InnateImmunologic FactorsLiver CirrhosisLiver NeoplasmsMaleMiddle AgedPrecancerous ConditionsCytokinesImmunologic FactorsCD40CytokinesHepatitis C virusHepatocellular carcinomaInterleukin-10Interleukin-2Myeloid dendritic cellsNatural killer cellNKG2DPlasmacytoid cells

Identifiers

PMID29568203
PMCPMC5859225
OpenAlexW2793345845

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.